Ads
related to: levodopa conversion to dopamine drugs- Important Safety Info
Read Important Safety, Dosing,
& Tolerability Information.
- Peer Perspectives
Hear Other Physicians' Experiences
Treating Parkinson's Off Time.
- Request a Representative
Want to Learn More? Submit a Form
to Speak to a Representative.
- HCP Instructions for Use
Visit to Access Downloadable Forms
to Help Your Patients Get Started.
- Important Safety Info
Search results
Results From The WOW.Com Content Network
Peripherally selective DDCIs incapable of crossing the protective blood–brain barrier (BBB) are used in augmentation of L-DOPA (levodopa) in the treatment of Parkinson's disease (PD) to block the conversion of L-DOPA into dopamine outside the brain, for the purpose of reducing adverse side effects. [3]
l-DOPA can be manufactured and in its pure form is sold as a drug with the INN Tooltip International Nonproprietary Name levodopa. Trade names include Sinemet, Pharmacopa, Atamet, and Stalevo. As a drug, it is used in the clinical treatment of Parkinson's disease and dopamine-responsive dystonia. l-DOPA has a counterpart with opposite chirality ...
The drug is a centrally permeable monoamine precursor and prodrug of dopamine and hence acts as a dopamine receptor agonist. [3] Chemically, levodopa is an amino acid, a phenethylamine, and a catecholamine. [3] Levodopa was first synthesized and isolated in the early 1910s. [3] The antiparkinsonian effects of levodopa were discovered in the ...
DopAmide, or L-DopAmide, is a synthetic levodopa (L-DOPA) analogue that can serve as a levodopa and dopamine prodrug and is of potential interest in the treatment of Parkinson's disease. [ 1 ] [ 2 ] [ 3 ] DopAmide has an amide rather than the carboxyl group of L -DOPA, [ 2 ] [ 3 ] which imparts greater water solubility .
Levodopa is the immediate precursor to dopamine. Entacapone is a selective, reversible catechol- O -methyltransferase (COMT) inhibitor that prevents the degradation of levodopa. Entacapone does not cross the blood–brain barrier.
XP-21279 is a sustained-release levodopa (L-DOPA) prodrug and hence a dopamine precursor and non-selective dopamine receptor agonist which was under development for the treatment of Parkinson's disease. [4] [1] [3] It is taken by mouth. [1] [2] [3]
Other medications that convert into dopamine, as opposed to functioning as dopamine analogs, alleviate the effects of the degeneration of dopamine-producing neurons. One dopamine precursor, Levodopa, was the first drug approved specifically for Parkinson's disease. [2] DRT increases dopamine in the brain to optimal levels in order to return ...
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Ad
related to: levodopa conversion to dopamine drugs